238 related articles for article (PubMed ID: 30362181)
21. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
[TBL] [Abstract][Full Text] [Related]
22. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
23. GlucoTab-guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes.
Aberer F; Lichtenegger KM; Smajic E; Donsa K; Malle O; Samonigg J; Höll B; Beck P; Pieber TR; Plank J; Mader JK
Diabetes Obes Metab; 2019 Mar; 21(3):584-591. PubMed ID: 30328252
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.
Shimoda S; Sakamoto W; Hokamura A; Matsuo Y; Sekigami T; Ichimori S; Iwashita S; Ishii N; Otsu K; Yoshimura R; Nishiyama T; Sakaguchi M; Nishida K; Araki E
Endocr J; 2019 Aug; 66(8):745-752. PubMed ID: 31308304
[TBL] [Abstract][Full Text] [Related]
25. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
Rautiainen P; Tirkkonen H; Laatikainen T
Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
[TBL] [Abstract][Full Text] [Related]
26. Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India.
Ghosal S; Sinha B; Gangopadhyay KK
Diabetes Metab Syndr; 2016; 10(3):161-5. PubMed ID: 26822462
[TBL] [Abstract][Full Text] [Related]
27. Insulin Degludec in Adolescents with Type 1 Diabetes: Is Newer Better? - A Retrospective Self-Control Case Series in Adolescents with a History of Diabetic Ketoacidosis.
Schmitt J; Scott ML
Horm Res Paediatr; 2019; 92(3):179-185. PubMed ID: 31865335
[TBL] [Abstract][Full Text] [Related]
28. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
[TBL] [Abstract][Full Text] [Related]
29. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
Sullivan SD; Nicholls CJ; Gupta RA; Menon AA; Wu J; Westerbacka J; Bosnyak Z; Frias JP; Bailey TS
Diabetes Obes Metab; 2019 Sep; 21(9):2123-2132. PubMed ID: 31144445
[TBL] [Abstract][Full Text] [Related]
30. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus.
Liu M; Zhou Z; Yan J; Li P; Song W; Fu J; Chen X; Zhao W; Xi L; Luo X; Sha L; Deng X; Gong C
BMC Endocr Disord; 2016 Nov; 16(1):67. PubMed ID: 27887605
[TBL] [Abstract][Full Text] [Related]
31. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
32. The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial.
Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Horiuchi R; Utsunomiya K
Diabetes Technol Ther; 2017 Aug; 19(8):457-462. PubMed ID: 28605286
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.
Danne T; Tamborlane WV; Malievsky OA; Franco DR; Kawamura T; Demissie M; Niemoeller E; Goyeau H; Wardecki M; Battelino T
Diabetes Care; 2020 Jul; 43(7):1512-1519. PubMed ID: 32430458
[TBL] [Abstract][Full Text] [Related]
34. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
[TBL] [Abstract][Full Text] [Related]
35. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
36. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
Ritzel R; Roussel R; Bolli GB; Vinet L; Brulle-Wohlhueter C; Glezer S; Yki-Järvinen H
Diabetes Obes Metab; 2015 Sep; 17(9):859-67. PubMed ID: 25929311
[TBL] [Abstract][Full Text] [Related]
37. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
[TBL] [Abstract][Full Text] [Related]
38. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
Owens DR; Luzio SD; Sert-Langeron C; Riddle MC
Diabetes Obes Metab; 2011 Nov; 13(11):1020-7. PubMed ID: 21679291
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
Blevins TC; Barve A; Sun B; Ankersen M
Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
[TBL] [Abstract][Full Text] [Related]
40. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
Diabetes Care; 2015 Dec; 38(12):2217-25. PubMed ID: 26084341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
